Phase I Clinical Study of Metatinib Tromethamine Tablet
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of
daily oral administration of metatinib tromethamine in subjects with solid tumors;
Investigate the influence of food on pharmacokinetic parameters.
Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral
administration of metatinib tromethamine in subjects with solid tumors; To observe
preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive
biomarkers at MTD.